证券之星消息，截至2025年9月19日收盘，春立医疗(688236)报收于22.88元，上涨0.88%，换手率 1.18%，成交量3.4万手，成交额7882.82万元。 该股最近90天内共有5家机构给出评级，买入评级5家；过去90天内机构目标均价为31.46。 | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-19 | 22.88 | 0.88% | 16.92万 | 0.21% | -20.05万 | -0.25% | 3.12万 | - 0.04% | | 2025-09-18 | 22.68 | -2.03% | -229.42万 | -5.21% | 67.17万 | 1.53% | 162.25万 | 3.69% | | 2025-09-17 | 23.15 | -1.45% | -197.25万 | -4.60% | -45.49万 | -1.06% | 242.75万 | 5.66% | | 2 ...

Group 1 - The core business of the company is focused on the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2] - As of June 30, 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 28.27%, and a net profit attributable to shareholders of 114 million yuan, with a year-on-year increase of 44.85% [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] Group 2 - As of September 18, 2023, the company's financing balance was 36.84 million yuan, accounting for 0.56% of its market capitalization, indicating a high level of financing activity [1] - The company had a total of 5,920 shareholders as of June 30, 2025, with a decrease of 17.57% compared to the previous period, while the average circulating shares per person increased by 341.41% [2] - The top ten circulating shareholders include significant institutional investors, with notable changes in holdings, such as an increase in shares held by Ping An Low Carbon Economy Mixed A [3]

| 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-09-18 | 4313.00万 | 14.62万 | 0.34% | | 2025-09-17 | 4298.38万 | -17.12万 | -0.40% | | 2025-09-16 | 4315.50万 | -10.82万 | -0.25% | | 2025-09-15 | 4326.32万 | 9.62万 | 0.22% | | 2025-09-12 | 4316.70万 | -12.75万 | -0.29% | 证券之星消息，9月18日南向资金增持14.62万股春立医疗（01858.HK）。近5个交易日中，获南向资金 减持的有3天，累计净减持16.45万股。近20个交易日中，获南向资金减持的有9天，累计净减持230.32万 股。截至目前，南向资金持有春立医疗（01858.HK）4313.0万股，占公司已发行普通股的45.32%。 北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品为关节假体产品及脊柱类植 ...

Core Viewpoint - The stock of Chunli Medical (688236) has experienced a decline in price and significant net outflow of funds, indicating potential investor concerns about its performance and market position [1][2]. Financial Performance - As of the latest report, Chunli Medical's total revenue for the first half of 2025 was 488 million yuan, representing a year-on-year increase of 28.27% [3]. - The net profit attributable to shareholders for the same period was 114 million yuan, up 44.85% year-on-year, while the net profit excluding non-recurring items reached 106 million yuan, marking a 61.09% increase [3]. - In Q2 2025, the company reported a single-quarter revenue of 258 million yuan, a significant year-on-year increase of 62.85%, and a net profit of approximately 56.4 million yuan, up 136.7% year-on-year [3]. Market Position and Valuation - Chunli Medical's total market capitalization is 8.699 billion yuan, which is below the industry average of 12.073 billion yuan, ranking 44 out of 123 in the medical device sector [3]. - The company's price-to-earnings (P/E) ratio is 38, compared to the industry average of 67.82, indicating a relatively lower valuation [3]. - The gross margin stands at 67.09%, significantly higher than the industry average of 51.85%, while the net margin is 23.48%, compared to the industry average of 10.39% [3]. Fund Flow Analysis - On September 18, 2025, Chunli Medical's stock price closed at 22.68 yuan, down 2.03%, with a turnover rate of 0.66% and a trading volume of 19,100 hands, resulting in a total transaction amount of approximately 43.997 million yuan [1]. - The net outflow of main funds on that day was 2.2942 million yuan, accounting for 5.21% of the total transaction amount, while retail investors saw a net inflow of 1.6225 million yuan, representing 3.69% of the total [1][2].

Group 1 - The core point of the news is that southbound funds have reduced their holdings in Chunli Medical (01858.HK) by 171,200 shares on September 17, 2025, marking a total net reduction of 251,000 shares over the last five trading days and 2,212,200 shares over the last twenty trading days [1][2] - As of now, southbound funds hold 42,983,800 shares of Chunli Medical, which represents 45.17% of the company's total issued ordinary shares [1][2] Group 2 - Chunli Medical is primarily engaged in the research, development, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, while its spinal implant products include a full range of spinal fixation systems [2] - Chunli Medical's products are exported to various countries and regions across Asia, South America, Africa, Oceania, and Europe [2]

Core Viewpoint - Spring Medical (688236) has experienced a decline in stock price and mixed capital flow, with a notable increase in revenue and profit in its recent financial report [1][4]. Group 1: Stock Performance - As of September 15, 2025, Spring Medical's stock closed at 23.2 yuan, down 2.93% with a turnover rate of 0.84% and a trading volume of 24,200 hands, amounting to a transaction value of 56.44 million yuan [1]. - The net inflow of main funds on September 15 was 221,300 yuan, accounting for 0.39% of the total transaction value, while retail investors saw a net outflow of 674,100 yuan, representing 1.19% of the total [1]. Group 2: Financing and Margin Trading - On September 15, the financing buy amounted to 5.95 million yuan, with a net financing buy of 2.56 million yuan, while the margin trading balance stood at 35.15 million yuan [1][2]. - The financing balance on September 15 was 35.14 million yuan, reflecting a decrease in financing net buy compared to previous days [2]. Group 3: Financial Performance - For the first half of 2025, Spring Medical reported a main revenue of 488 million yuan, a year-on-year increase of 28.27%, and a net profit of 114 million yuan, up 44.85% [4]. - The company's gross profit margin was 67.09%, significantly higher than the industry average of 51.85%, indicating strong profitability [4]. Group 4: Industry Comparison - Spring Medical's total market value is 8.899 billion yuan, which is lower than the industry average of 12.186 billion yuan, ranking 44th out of 123 companies in the medical device sector [4]. - The company's price-to-earnings ratio (P/E) is 38.87, which is more favorable compared to the industry average of 69.25, ranking 45th in the industry [4].

Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Spring Medical, indicating a slight increase in stock price and a net financing outflow on September 11 [1] - On September 11, Spring Medical's stock rose by 1.94%, with a trading volume of 48.86 million yuan, while the financing buy-in was 3.26 million yuan and the financing repayment was 4.63 million yuan, resulting in a net financing outflow of 1.37 million yuan [1] - As of September 11, the total balance of margin trading for Spring Medical was 30.93 million yuan, with the financing balance accounting for 0.44% of the circulating market value, which is below the 50th percentile level over the past year, indicating a low financing level [1] Group 2 - Spring Medical, established on February 12, 1998, is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - The company reported a revenue of 488 million yuan for the first half of 2025, representing a year-on-year growth of 28.27%, and a net profit attributable to shareholders of 114 million yuan, reflecting a year-on-year increase of 44.85% [2] - As of June 30, 2025, the number of shareholders for Spring Medical was 5,920, a decrease of 17.57% from the previous period, while the average circulating shares per person increased by 341.41% to 48,836 shares [2] Group 3 - Spring Medical has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] - As of June 30, 2025, among the top ten circulating shareholders, Ping An Low Carbon Economy Mixed A ranked fourth with 3.77 million shares, an increase of 2.77 million shares from the previous period, while Southern Medical Health Flexible Allocation Mixed A entered the list as the ninth largest shareholder with 1.60 million shares [3] - Notably, Zhonggeng Small Cap Value Stock and Hong Kong Central Clearing Limited exited the top ten circulating shareholders list [3]

Core Viewpoint - The stock of Chunli Medical (688236) has shown a positive performance with a closing price of 24.16 yuan, reflecting a 1.94% increase on September 11, 2025, despite some net outflows from major and retail investors [1][2]. Financial Performance - Chunli Medical reported a main revenue of 488 million yuan for the first half of 2025, representing a year-on-year increase of 28.27% [2]. - The net profit attributable to shareholders reached 114 million yuan, up 44.85% year-on-year, while the net profit after deducting non-recurring gains and losses was 106 million yuan, increasing by 61.09% [2]. - In Q2 2025, the company achieved a single-quarter main revenue of 258 million yuan, a significant rise of 62.85% year-on-year, with a net profit of approximately 56.4 million yuan, marking a 136.7% increase [2]. Market Position - Chunli Medical's total market capitalization stands at 9.267 billion yuan, which is below the industry average of 12.288 billion yuan, ranking 40th out of 123 companies in the medical device sector [2]. - The company has a price-to-earnings ratio (P/E) of 40.48, which is more favorable compared to the industry average of 67.38, ranking 47th in the industry [2]. - The gross margin of Chunli Medical is 67.09%, significantly higher than the industry average of 51.85%, ranking 27th in the sector [2]. Investor Sentiment - Over the past 90 days, four institutions have rated Chunli Medical with a "buy" recommendation, with an average target price of 28.32 yuan [3].

Core Viewpoint - Spring Medical is a leading domestic orthopedic medical device manufacturer focusing on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, with ongoing development of customized dental implants [2][3] Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, is located in Tongzhou District, Beijing, specializing in implantable orthopedic medical devices [7][8] - The company's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [2][3][8] Financial Performance - For the first half of 2025, Spring Medical achieved operating revenue of 488 million yuan, representing a year-on-year growth of 28.27%, and a net profit attributable to shareholders of 114 million yuan, up 44.85% year-on-year [8] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan in the last three years [8] Market Position and Recognition - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position, innovation capabilities, and high market share [3] - The company is actively involved in the smart medical field, having obtained registration certificates for hip and knee surgical robots and medical image processing software [2][3] Stock Performance - On September 11, Spring Medical's stock rose by 1.94%, with a trading volume of 48.86 million yuan and a market capitalization of 9.267 billion yuan [1] - The average trading cost of the stock is 20.64 yuan, with the current price fluctuating between resistance at 25.91 yuan and support at 22.65 yuan [6]

Core Viewpoint - The stock of Chunli Medical (688236) has shown a decline in price and mixed capital flow, with significant institutional buy ratings and strong financial performance in recent reports [1][2][3]. Group 1: Stock Performance - As of September 10, 2025, Chunli Medical's stock closed at 23.7 yuan, down 0.84%, with a turnover rate of 0.52% and a trading volume of 14,900 hands, resulting in a transaction amount of 35.17 million yuan [1]. - The net outflow of main funds on September 10 was 3.95 million yuan, accounting for 11.24% of the total transaction amount, while retail investors saw a net inflow of 2.98 million yuan, representing 8.48% of the total [1]. Group 2: Financial Performance - Chunli Medical reported a main revenue of 488 million yuan for the first half of 2025, an increase of 28.27% year-on-year, and a net profit attributable to shareholders of 114 million yuan, up 44.85% year-on-year [2]. - The company achieved a gross profit margin of 67.09% and a net profit margin of 23.48%, indicating strong profitability compared to industry averages [2]. Group 3: Industry Comparison - Chunli Medical's total market value is 9.09 billion yuan, which is below the industry average of 12.11 billion yuan, ranking 40th out of 123 companies in the medical device sector [2]. - The company's price-to-earnings ratio (P/E) stands at 39.71, significantly lower than the industry average of 66.41, ranking 46th in the industry [2]. Group 4: Analyst Ratings - In the last 90 days, four institutions have given buy ratings for Chunli Medical, with an average target price of 28.32 yuan [3].